Announcements Trials
Browse Landscape

Phase

Phase 3 1

Status

Completed 3Withdrawn 1Terminated 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Lymphoid 1

Conditions

Lymphoproliferative Disorders 1Lymphoma, T-Cell, Peripheral 1Lymphoma, T-Cell 1Lymphoma, Non-Hodgkin 1Lymphoma 1

Interventions

Rituximab 70Cyclophosphamide 46fludarabine 21fludarabine phosphate 20Mycophenolic Acid 20Etoposide 18Whole-Body Irradiation 17Filgrastim 15Radiotherapy 14Antilymphocyte Serum 14Tacrolimus 13Melphalan 13Gemcitabine 13Cyclosporine 13Busulfan 13Methotrexate 12Lenalidomide 12Bortezomib 12Bendamustine Hydrochloride 11Vincristine 10Peripheral Blood Stem Cell Transplantation 10Cytarabine 10Doxorubicin 8Dexamethasone 8venetoclax 7thymoglobulin 7pembrolizumab 7Thiotepa 7Methylprednisolone 7Granulocyte Colony-Stimulating Factor 7

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Terminated × Lymphoma, Non-Hodgkin × 10-propargyl-10-deazaaminopterin × Clear all
NCT01420679 2021-11-19

Pralatrexate vs Observation Following CHOP-based Chemotherapy in Undiagnosed Peripheral T-cell Lymphoma Patients

Spectrum Pharmaceuticals, Inc

Phase 3 Terminated
21 enrolled 8 charts
Lymphoid

Lymphoma, Lymphoma, Non-Hodgkin, Lymphoproliferative Disorders, Lymphoma, T-Cell, Lymphoma, T-Cell, Peripheral

Data powered by HemOnc (CC BY 4.0) Colophon âš¡